Pliant Therapeutics, Inc.
PLRX
$1.35
$0.043.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -60.82% | -27.55% | -10.84% | 1.66% | 4.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -74.72% | -54.25% | -24.81% | 12.49% | 13.36% |
| Operating Income | 74.72% | 54.25% | 24.81% | -12.49% | -13.36% |
| Income Before Tax | 52.59% | 54.47% | 22.48% | -19.62% | -20.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.59% | 54.47% | 22.48% | -19.62% | -20.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.59% | 54.47% | 22.48% | -19.62% | -20.98% |
| EBIT | 74.72% | 54.25% | 24.81% | -12.49% | -13.36% |
| EBITDA | 75.20% | 54.57% | 24.78% | -12.74% | -13.50% |
| EPS Basic | 53.05% | 54.97% | 23.74% | -17.59% | -19.09% |
| Normalized Basic EPS | 76.80% | 54.80% | 23.73% | -17.60% | -19.10% |
| EPS Diluted | 53.05% | 54.97% | 23.74% | -17.59% | -19.09% |
| Normalized Diluted EPS | 76.80% | 54.80% | 23.73% | -17.60% | -19.10% |
| Average Basic Shares Outstanding | 0.98% | 1.11% | 1.66% | 1.73% | 1.59% |
| Average Diluted Shares Outstanding | 0.98% | 1.11% | 1.66% | 1.73% | 1.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |